Tandem Diabetes Care Maps Pharmacy Shift, Targets 65% Gross Margin and 2026 Mobi Tubeless Launch

Core Insights - Tandem Diabetes Care is shifting its business model towards the pharmacy channel, expecting significant growth in pharmacy sales from 10% in 2026 to about 70% over the next two to three years, which will enhance gross margins significantly [1][7]. Group 1: Business Model Shift - The company anticipates a major shift in its business model starting in 2026, with supplies moving into the pharmacy channel, allowing patients to obtain a pump at no cost if they choose Tandem [1]. - Currently, pharmacy volume is small, with less than 5% of customers ordering supplies through pharmacies, yet it represents about 7% of company sales [2]. - The company has begun to see financial benefits from its early steps into the pharmacy channel, validating its assumptions about the benefits for patients and physicians [3]. Group 2: Financial Performance - Tandem recorded its highest gross margin to date at 58% in Q4, driven by the shift to the pharmacy channel [2][7]. - The company expects to achieve a gross margin of around 60% by the end of this year and aims to reach its long-standing target of 65% gross margin sooner than previously planned due to the pharmacy opportunity [7]. Group 3: Product Development and Roadmap - Tandem is on track to submit the Mobi tubeless device in Q2 and plans to launch it in the second half of 2026, while also advancing the Sigi device as a next-generation offering [5][12]. - The company intends to offer both tubed and tubeless options, with the tubeless segment growing faster than the tubed segment [11]. Group 4: Market Strategy and Expansion - Tandem has contracts with the three major pharmacy benefit managers (PBMs), covering approximately 80% of lives, and is pursuing a pay-as-you-go model with a net-price assumption near $350 per month [6][8]. - The company is investing in international markets and expects to expand its sales and marketing efforts significantly in 2025 [14]. Group 5: Upcoming Catalysts - The company plans to showcase product and integration updates at the American Diabetes Association (ADA) meeting in June, including sensor integrations and further discussions on Type 2 diabetes progress in the U.S. market [15][16].